Regen BioPharma Inc (RGBP)
Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014
Balance Sheet Date2025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-312018-Dec-312018-Sep-302018-Jun-302018-Mar-312017-Dec-312017-Sep-302017-Jun-302017-Mar-312016-Dec-312016-Sep-302016-Jun-302016-Mar-312015-Dec-312015-Sep-302015-Jun-302015-Mar-312014-Dec-312014-Sep-302014-Jun-302013-Sep-30
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016Q2-FY2016Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014Q3-FY2014Q2-FY2014
Total Assets274,628$196,841$169,482$191,416$161,084$170,150$140,770$353,617$178,015$150,602$123,189$95,475$95,475$41,007$99,087$114,304$43,893$182,245$209,018$558,808$757,061$1,149,280$944,239$965,562$598,498$706,658$319,356$250,646$192,853$318,249$220,452$228,003$534,809$64,537$10,655$51,631$122,789$
Total Current Assets274,628$179,108$151,749$173,683$143,351$152,417$123,037$131,037$158,046$130,633$103,220$75,506$75,506$21,038$79,117$45,361$31,226$107,215$42,771$90,556$270,409$643,428$478,387$570,562$278,498$394,658$207,356$170,646$136,053$198,249$62,052$228,003$534,809$64,537$10,655$51,631$122,789$
Cash and Cash Equivalents69,555$135$716$121,037$0$0$0$0$0$357$7,855$1,812$15,090$39,095$8,019$55,404$31,074$261,708$269,973$401,627$113,159$24,822$106,024$168,517$38,620$521,974$53,622$0$49,395$
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets0$17,733$17,733$17,733$17,733$17,733$17,733$222,580$19,969$19,969$19,969$19,969$19,969$19,969$19,970$68,943$12,667$75,030$166,247$468,252$486,652$505,852$465,852$395,000$320,000$312,000$112,000$80,000$56,800$120,000$158,400$0$0$0$0$0$0$
Goodwill
Other Intangible Assets
Physical Assets
Other Noncurrent Assets
Assets Held for Sale in Long Term
Total Liabilities6,555,811$6,012,532$5,867,880$5,870,459$5,378,456$5,327,862$5,316,734$5,457,616$5,248,729$5,731,858$7,458,187$8,654,546$8,654,546$7,740,454$11,007,882$12,900,392$8,866,365$8,846,425$9,330,689$9,133,637$9,594,521$8,949,512$6,195,573$4,984,293$2,062,104$862,779$906,258$752,053$448,254$340,225$317,639$145,281$180,070$325,919$140,286$57,460$7,597$
Total Current Liabilities6,555,811$6,012,532$5,867,880$5,870,459$5,378,456$5,327,862$5,173,049$5,308,002$5,248,729$5,731,858$7,458,187$8,654,546$8,654,546$7,740,454$11,002,904$12,367,719$7,972,129$8,000,434$8,673,511$8,623,396$9,182,075$8,472,887$5,863,164$4,751,036$1,899,918$733,004$799,201$649,350$389,959$340,225$317,639$145,281$180,070$325,919$140,286$57,460$7,597$
Accounts Payable1,714$30,477$33,703$36,005$29,669$29,416$29,798$29,673$117,131$113,855$110,486$107,430$107,430$99,156$92,000$94,548$78,707$81,275$80,567$74,044$363,710$561,903$495,749$553,796$448,454$163,927$240,759$147,621$20,783$27,646$25,854$1,190$16,207$3,501$3,305$117$833$
Short Term Debt
Short Term Capital Lease Obligations
Other Current Liabilities41,423$41,423$41,423$41,423$41,423$41,423$41,423$
Total Noncurrent Liabilities0$0$0$0$0$0$143,685$149,614$0$0$0$0$0$0$4,978$532,673$894,236$845,991$657,178$510,241$412,446$476,625$332,409$233,257$162,186$129,775$107,057$102,703$58,295$0$0$0$0$0$0$0$0$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity(6,281,183$)(5,815,691$)(5,698,399$)(5,679,043$)(5,217,372$)(5,157,713$)(5,175,963$)(5,241,483$)(5,104,000$)(5,028,973$)(4,929,755$)(4,884,827$)(8,036,059$)(5,070,714$)(5,581,256$)(7,334,998$)(8,559,071$)(11,769,440$)(7,699,447$)(10,908,795$)(12,786,088$)(8,814,475$)(8,656,832$)(9,121,671$)(8,567,198$)(8,546,711$)(7,800,232$)(5,251,335$)(3,927,477$)(1,371,121$)(142,417$)(586,902$)(570,226$)(255,902$)(21,976$)(97,187$)82,722$354,739$(261,382$)(129,631$)(5,829$)115,192$
Equity to Minority0$15,642$2,934$0$
Equity to Common Shareholders(6,281,183$)(5,815,691$)(5,698,399$)(5,679,043$)(5,217,372$)(5,157,713$)(5,175,962$)(5,241,483$)(5,103,999$)(5,028,973$)(4,929,755$)(4,884,827$)(8,036,059$)(5,070,713$)(5,581,256$)(7,334,998$)(8,559,070$)(11,769,440$)(7,699,447$)(10,908,795$)(12,792,604$)(8,820,991$)(8,661,761$)(9,121,671$)(8,567,198$)(8,546,711$)(7,800,232$)(5,251,335$)(3,927,477$)(1,371,121$)(142,417$)(586,902$)(570,226$)(255,902$)(21,976$)(97,187$)82,722$354,739$(261,382$)(129,631$)(5,829$)115,192$
Additional Paid-In Capital15,628,062$15,504,134$15,455,134$15,455,134$15,403,050$14,456,692$14,308,349$14,644,467$8,331,313$8,330,647$8,313,877$8,298,393$8,298,393$8,305,609$8,261,993$8,240,724$7,848,424$7,690,918$7,517,888$7,055,513$6,950,792$6,837,981$6,642,979$6,591,720$6,516,720$21,714,779$18,961,259$16,634,372$14,551,402$13,632,102$11,663,905$11,209,694$9,905,102$507,523$485,097$485,097$485,097$
Retained Earnings(21,691,620$)(21,119,151$)(20,951,859$)(20,932,504$)(20,417,118$)(20,351,216$)(20,221,096$)(19,748,863$)(14,475,117$)(14,917,300$)(16,583,666$)(17,786,519$)(17,786,519$)(16,915,318$)(19,998,086$)(21,861,598$)(17,459,047$)(17,126,808$)(17,457,044$)(16,483,071$)(16,658,594$)(15,526,990$)(12,741,843$)(11,489,821$)(8,867,646$)(22,748,898$)(20,224,319$)(17,778,660$)(15,421,576$)(14,331,191$)(12,473,725$)(11,873,041$)(10,310,670$)(1,497,768$)(1,278,577$)(1,083,975$)(917,954$)
Treasury Stock
Capital Lease Obligations